Technical Analysis for ABEO - Abeona Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Outside Day | Range Expansion | 12.14% | |
| Wide Bands | Range Expansion | 12.14% | |
| NR7 | Range Contraction | 9.53% | |
| Narrow Range Bar | Range Contraction | 9.53% | |
| Inside Day | Range Contraction | 9.53% | |
| Wide Bands | Range Expansion | 9.53% | |
| Earnings Movers | Other | 12.14% |
| Alert | Time |
|---|---|
| Up 1 ATR | about 21 hours ago |
| Up 10% | about 21 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
| Rose Above 20 DMA | about 22 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/09/2024
Abeona Therapeutics Inc. Description
Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Biology Emerging Technologies Rare Diseases Molecular Biology Genetics Gene Therapy Genetic Engineering Anemia CRISPR Genome Editing Adeno Associated Virus Cas9 Severe And Rare Diseases Blood Diseases Fanconi Anemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.01 |
| 52 Week Low | 2.85 |
| Average Volume | 766,225 |
| 200-Day Moving Average | 5.08 |
| 50-Day Moving Average | 6.46 |
| 20-Day Moving Average | 4.56 |
| 10-Day Moving Average | 4.43 |
| Average True Range | 0.58 |
| RSI (14) | 44.75 |
| ADX | 18.9 |
| +DI | 25.68 |
| -DI | 24.58 |
| Chandelier Exit (Long, 3 ATRs) | 6.71 |
| Chandelier Exit (Short, 3 ATRs) | 4.79 |
| Upper Bollinger Bands | 7.21 |
| Lower Bollinger Band | 1.91 |
| Percent B (%b) | 0.53 |
| BandWidth | 116.10 |
| MACD Line | -0.59 |
| MACD Signal Line | -0.71 |
| MACD Histogram | 0.1194 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.76 | ||||
| Resistance 3 (R3) | 5.72 | 5.33 | 5.59 | ||
| Resistance 2 (R2) | 5.33 | 5.06 | 5.35 | 5.53 | |
| Resistance 1 (R1) | 5.02 | 4.90 | 5.18 | 5.06 | 5.47 |
| Pivot Point | 4.63 | 4.63 | 4.71 | 4.65 | 4.63 |
| Support 1 (S1) | 4.32 | 4.36 | 4.48 | 4.36 | 3.95 |
| Support 2 (S2) | 3.93 | 4.20 | 3.95 | 3.89 | |
| Support 3 (S3) | 3.62 | 3.93 | 3.84 | ||
| Support 4 (S4) | 3.66 |
